[go: up one dir, main page]

WO1997030146A3 - Cardiotrophine et ses utilisations - Google Patents

Cardiotrophine et ses utilisations Download PDF

Info

Publication number
WO1997030146A3
WO1997030146A3 PCT/US1997/002675 US9702675W WO9730146A3 WO 1997030146 A3 WO1997030146 A3 WO 1997030146A3 US 9702675 W US9702675 W US 9702675W WO 9730146 A3 WO9730146 A3 WO 9730146A3
Authority
WO
WIPO (PCT)
Prior art keywords
disorders
lifrβ
receptor
cardiotrophin
neurological
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US1997/002675
Other languages
English (en)
Other versions
WO1997030146A2 (fr
Inventor
Joffre Baker
Kenneth Chien
Kathleen King
Diane Pennica
William Wood
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genentech Inc
University of California Berkeley
University of California San Diego UCSD
Original Assignee
Genentech Inc
University of California Berkeley
University of California San Diego UCSD
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc, University of California Berkeley, University of California San Diego UCSD filed Critical Genentech Inc
Priority to EP97907730A priority Critical patent/EP0885294A2/fr
Priority to CA 2245635 priority patent/CA2245635A1/fr
Priority to AU19654/97A priority patent/AU733403B2/en
Priority to JP9529601A priority patent/JP2000504729A/ja
Priority to IL12554897A priority patent/IL125548A/en
Publication of WO1997030146A2 publication Critical patent/WO1997030146A2/fr
Publication of WO1997030146A3 publication Critical patent/WO1997030146A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0603—Embryonic cells ; Embryoid bodies
    • C12N5/0606—Pluripotent embryonic cells, e.g. embryonic stem cells [ES]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/34—Muscles; Smooth muscle cells; Heart; Cardiac stem cells; Myoblasts; Myocytes; Cardiomyocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/204—IL-6
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/06—Antiabortive agents; Labour repressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/115—Basic fibroblast growth factor (bFGF, FGF-2)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/125—Stem cell factor [SCF], c-kit ligand [KL]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/175—Cardiotrophin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Developmental Biology & Embryology (AREA)
  • Cell Biology (AREA)
  • Reproductive Health (AREA)
  • Gynecology & Obstetrics (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Neurosurgery (AREA)
  • Vascular Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Virology (AREA)
  • Rheumatology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Microbiology (AREA)
  • Neurology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)

Abstract

CT-1 isolée, ADN isolé codant cette CT-1 et méthodes d'élaboration par recombinaison ou par synthèse de cette CT-1. La CT-1 est connue pour se lier au récepteur LIFRβ et pour l'activer. Ces molécules CT-1 sont connues pour exercer une influence sur l'activité hypertrophique, l'activité neurologique et d'autres activités liées au récepteur LIFRβ. En conséquence, ces composés ou leurs antagonistes peuvent être utilisés pour le traitement de l'insuffisance cardiaque, des troubles arythmiques, inotropes et neurologiques ou autres associés au récepteur LIFRβ.
PCT/US1997/002675 1996-02-14 1997-02-11 Cardiotrophine et ses utilisations Ceased WO1997030146A2 (fr)

Priority Applications (5)

Application Number Priority Date Filing Date Title
EP97907730A EP0885294A2 (fr) 1996-02-14 1997-02-11 Cardiotrophine et ses utilisations
CA 2245635 CA2245635A1 (fr) 1996-02-14 1997-02-11 Cardiotrophine et ses utilisations
AU19654/97A AU733403B2 (en) 1996-02-14 1997-02-11 Cardiotrophin and uses therefor
JP9529601A JP2000504729A (ja) 1996-02-14 1997-02-11 カルジオトロフィンとその使用法
IL12554897A IL125548A (en) 1996-02-14 1997-02-11 Cardiotrophin-1 compositions and uses thereof for treatment of mammalian cells

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US60139596A 1996-02-14 1996-02-14
US08/601,395 1996-02-14

Publications (2)

Publication Number Publication Date
WO1997030146A2 WO1997030146A2 (fr) 1997-08-21
WO1997030146A3 true WO1997030146A3 (fr) 1997-10-09

Family

ID=24407322

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1997/002675 Ceased WO1997030146A2 (fr) 1996-02-14 1997-02-11 Cardiotrophine et ses utilisations

Country Status (6)

Country Link
EP (1) EP0885294A2 (fr)
JP (1) JP2000504729A (fr)
AU (1) AU733403B2 (fr)
IL (1) IL125548A (fr)
WO (1) WO1997030146A2 (fr)
ZA (1) ZA971226B (fr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6472585B1 (en) 1994-04-25 2002-10-29 Genentech, Inc. Cardiotrophin-1 defective mouse
US7258983B2 (en) 1994-04-25 2007-08-21 Genentech, Inc. Cardiotrophin-1 compositions and methods for the treatment of tumor
JP2002534987A (ja) * 1999-01-21 2002-10-22 ジェネンテック・インコーポレーテッド 腫瘍の治療のための組成物と方法
AU2004294572A1 (en) 2003-11-26 2005-06-16 Merck Serono Sa Use of IL-6-type cytokines for maturation of oocytes
AU2005327507A1 (en) * 2005-02-15 2006-08-24 Apollo Life Sciences Limited A molecule and chimeric molecules thereof
JP6754966B2 (ja) * 2016-02-25 2020-09-16 国立大学法人広島大学 始原生殖細胞の培養方法及び始原生殖細胞の培養用培地添加物
US9962427B2 (en) 2016-07-11 2018-05-08 Ottawa Hospital Research Institute Treatment of right ventricular dysfunction due to pressure overload

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995029237A1 (fr) * 1994-04-25 1995-11-02 Genentech, Inc. Cardiotrophine et ses utilisations

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995029237A1 (fr) * 1994-04-25 1995-11-02 Genentech, Inc. Cardiotrophine et ses utilisations

Also Published As

Publication number Publication date
AU733403B2 (en) 2001-05-10
WO1997030146A2 (fr) 1997-08-21
IL125548A (en) 2004-07-25
IL125548A0 (en) 1999-03-12
JP2000504729A (ja) 2000-04-18
AU1965497A (en) 1997-09-02
EP0885294A2 (fr) 1998-12-23
ZA971226B (en) 1998-08-13

Similar Documents

Publication Publication Date Title
MX9604985A (es) Cardiotropina y usos de la misma.
EP0335637A3 (fr) Peptides facteurs de croissance des nerfs
WO1996018738A3 (fr) PROBINE TYROSINE KINASE (PYK2), SON CLONAGE PAR ADNc ET SON UTILISATION
MY131442A (en) Excitatory amino acid receptor antagonists
WO1992013878A3 (fr) Produits mimetiques de conformation restreinte de tours beta et bombements beta, et peptides les contenant
WO2001060806A3 (fr) Arylpyrazines substitues
NZ329627A (en) 8-Heterocyclically substituted 1,3,8-triaza-spiro[4.5]decan-4-ones
EP0849361A3 (fr) Nouveaux ligands du recepteur de neuropeptides HFGAN72
CA2141060A1 (fr) Insertion de gmp cyclique; phosphodiesterase et methodes specifiques pour gmp cyclique
WO1995014089A3 (fr) Cck-2, recepteur a tyrosine-kinase
BG105012A (en) N-linked sulphonamides of n-heterocyclic carboxylic acids or carboxylic isosteres
AU2028497A (en) Metabotropic gaba{b} receptors, receptor-specific ligands and their uses
WO1997030146A3 (fr) Cardiotrophine et ses utilisations
AU1266497A (en) Mutant human growth hormones and their uses
EP0787988A3 (fr) Particules avec une substance active immobilisée et procédé de purification de protéines
AU2384500A (en) Compounds, methods of screening and methods of treatment for central and peripheral nervous system disorders
WO1998011234A3 (fr) Proteines kinases humaines
EP0319315A3 (fr) Domaine du facteur VIII liant le facteur de von Willebrand
AU2458988A (en) The preparation, by genetic manipulation, of anticoagulative protein pp4
DE69422928D1 (de) Modifizierte maxadilan-protein, dessen herstellung und verwendung, und dem protein kodierende dns
BG105014A (en) Ureas and carbamates of n-heterocyclic carboxylic acids and carboxylic acid isosteres
WO2001016317A3 (fr) Molecules induites par un hydrocarbure aromatique polycyclique
ATE256126T1 (de) 5-heteroatom-alkyl substituierte 3-oxo-pyrido(1,2-a)benzimidazol-4-carboxamid derivate zur behandlung zentral nervöser system störungen
WO2001007431A3 (fr) Derives de benzothiophene
DE59708511D1 (de) Verwendung von 7-(1-aminomethyl-2-oxa-7-aza-bicyclo 3.3.0]oct-7-yl)-chinoloncarbonsäure- und -naphthyridoncarbonsäure-derivaten zur therapie von helicobacter-pylori-infektionen und den damit assoziierten gastroduodenalen erkrankungen

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE HU IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK TJ TM TR TT UA UG UZ VN YU AM AZ BY KG KZ MD RU TJ TM

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): KE LS MW SD SZ UG AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG

AK Designated states

Kind code of ref document: A3

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE HU IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK TJ TM TR TT UA UG UZ VN YU AM AZ BY KG KZ MD RU TJ TM

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): KE LS MW SD SZ UG AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

ENP Entry into the national phase

Ref document number: 2245635

Country of ref document: CA

Ref country code: CA

Ref document number: 2245635

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 1997907730

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1997907730

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 1997907730

Country of ref document: EP